Novartis Investigative Site

Pokfulam, Hong Kong

0 studies enrolling now · 6 studies all time

What they study most

ALK-positive Non-small Cell Lung Cancer, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Breast Cancer, Cardiovascular Disease and Lipoprotein(a), Chronic Myelogenous Leukemia, Hypereosinophilic Syndrome, Non-small Cell Lung Cancer, Pulmonary Disease, Chronic Obstructive, Systemic Mastocytosis

Studies at this site

• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients — Completed
• PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients — Stopped early
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies — Completed
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges — Completed